Markers of Natural Killer Cell Exhaustion in HIV/HCV Coinfection and Their Dynamics After HCV Clearance Mediated by Direct-Acting Antivirals

被引:0
作者
Osegueda, Ariel [1 ,2 ]
Polo, Maria Laura [1 ,2 ]
Baquero, Lucia [1 ,3 ]
Urioste, Alejandra [1 ,2 ]
Ghiglione, Yanina [1 ,2 ]
Paz, Silvia [4 ]
Poblete, Gabriela [4 ]
Gonzalez Polo, Virginia [1 ,2 ]
Turk, Gabriela [1 ,3 ]
Quiroga, Maria Florencia [1 ,3 ]
Laufer, Natalia [1 ,3 ,5 ]
机构
[1] Univ Buenos Aires, Inst Invest Biomed Retrovirus & SIDA INBIRS, CONICET, Buenos Aires, Argentina
[2] Univ Buenos Aires, Fac Med, Buenos Aires, Argentina
[3] Univ Buenos Aires, Dept Microbiol Parasitol & Inmunol, Fac Med, Buenos Aires, Argentina
[4] Hosp Francisco Javier Muniz, Buenos Aires, DF, Argentina
[5] Univ Buenos Aires, Fac Med, Inst Invest Biomed Retrovirus & SIDA, Paraguay 2155 Piso 11,C1121ABG, Buenos Aires, Argentina
来源
OPEN FORUM INFECTIOUS DISEASES | 2023年 / 10卷 / 12期
关键词
direct-acting antivirals; HIV/HCV coinfection; immunology; liver fibrosis; NK cell exhaustion; FIBROSIS; MORTALITY;
D O I
10.1093/ofid/ofad591
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background Liver fibrosis is a leading cause of morbimortality in people with HIV/hepatitis C virus (HCV). Natural killer (NK) cells are linked with amelioration of liver fibrosis; however, NK cells from individuals coinfected with HIV/HCV with cirrhosis display impaired functionality and high PD-1 expression. Here, we aimed to study PD-1, TIGIT, and Tim3 as potential exhaustion markers in NK cells from persons coinfected with HIV/HCV with mild and advanced liver fibrosis. We also evaluated the role of PD-1 expression on NK cells after HCV clearance by direct-acting antivirals (DAAs).Methods Peripheral blood mononuclear cells were isolated from individuals coinfected with HIV/HCV (N = 54; METAVIR F0/F1, n = 27; F4, evaluated by transient elastography, n = 27). In 26 participants, samples were collected before, at the end of, and 12 months after successful DAA treatment. The frequency, immunophenotype (PD-1, TIGIT, and Tim3 expression), and degranulation capacity (CD107a assay) of NK cells were determined by flow cytometry.Results Unlike PD-1, Tim3 and TIGIT were comparably expressed between persons with mild and advanced fibrosis. Degranulation capacity was diminished in NK/TIGIT+ cells in both fibrosis stages, while NK/PD-1+ cells showed a lower CD107a expression in cirrhotic cases. Twelve months after DAA treatment, those with advanced fibrosis showed an improved NK cell frequency and reduced NK/PD-1+ cell frequency but no changes in CD107a expression. In individuals with mild fibrosis, neither PD-1 nor NK cell frequency was modified, although the percentage of NK/CD107a+ cells was improved at 12 months posttreatment.Conclusions Although DAA improved exhaustion and frequency of NK cells in cirrhotic cases, functionality was reverted only in mild liver fibrosis, remarking the importance of an early DAA treatment. PD-1 and TIGIT are associated with impaired natural killer (NK) cell functionality in individuals coinfected with HIV/HCV. NK cell degranulation capacity improved in persons with mild fibrosis after direct-acting antiviral treatment. In cases of cirrhosis, although frequency of NK cells was restored, loss of functionality was not.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] The utility of HCV core antigen for evaluation of viremia at 48 weeks posttreatment with direct-acting antivirals
    Ko, Ping-Hung
    Tseng, Chih-Wei
    Tseng, Kuo-Chih
    Chen, Yen-Chun
    Hsu, Ching-Sheng
    ADVANCES IN DIGESTIVE MEDICINE, 2023, 10 (02) : 80 - 86
  • [42] Performance of hepatitis C virus (HCV) direct-acting antivirals in clinical trials and daily practice
    Arends, J. E.
    Kracht, P. A. M.
    Hoepelman, A. I. M.
    CLINICAL MICROBIOLOGY AND INFECTION, 2016, 22 (10) : 846 - 852
  • [43] Telemedicine HCV treatment in department of corrections results in high SVR in era of direct-acting antivirals
    Syed, Taseen A.
    Cherian, Reena
    Lewis, Shawn
    Sterling, Richard K.
    JOURNAL OF VIRAL HEPATITIS, 2021, 28 (01) : 209 - 212
  • [44] Pangenotypic triple versus double therapy in HCV-infected patients after prior failure of direct-acting antivirals
    Flisiak, Robert
    Zarebska-Michaluk, Dorota
    Berak, Hanna
    Dybowska, Dorota
    Sitko, Marek
    Parfieniuk-Kowerda, Anna
    Janocha-Litwin, Justyna
    Janczewska, Ewa
    Piekarska, Anna
    Lorenc, Beata
    Mazur, Wlodzimierz
    Dobrowolska, Krystyna
    Tudrujek-Zdunek, Magdalena
    Klapaczynski, Jakub
    Jaroszewicz, Jerzy
    CLINICAL AND EXPERIMENTAL HEPATOLOGY, 2023, 9 (03) : 193 - 201
  • [45] Long-term Effect of the HCV Elimination With Direct-acting Antivirals on the Progression of Gastroesophageal Varices
    Yuri, Yukihisa
    Nishimura, Takashi
    Ikeda, Naoto
    Takashima, Tomoyuki
    Aizawa, Nobuhiro
    Kimura, Taro
    Yoshihara, Kohei
    Yoshioka, Ryota
    Kawata, Shoki
    Kawase, Yuta
    Nakano, Ryota
    Shiomi, Hideyuki
    Fukunishi, Shinya
    Shinzaki, Shinichiro
    Enomoto, Hirayuki
    IN VIVO, 2024, 38 (06): : 2968 - 2972
  • [46] Direct-acting antivirals for HCV treatment in older patients: A systematic review and meta-analysis
    Villani, Rosanna
    Monami, Matteo
    Di Cosimo, Francesca
    Fioravanti, Gilda
    Mannucci, Edoardo
    Vendemiale, Gianluigi
    Serviddio, Gaetano
    JOURNAL OF VIRAL HEPATITIS, 2019, 26 (11) : 1249 - 1256
  • [47] Hepatocellular Carcinoma After HCV Eradication with Direct-Acting Antivirals: A Reappraisal Based on New Parameters to Assess the Persistence of Risk
    Fassio, Eduardo
    Colombato, Luis
    Gualano, Gisela
    Perez, Soledad
    Puga-Tejada, Miguel
    Landeira, Graciela
    CANCERS, 2025, 17 (06)
  • [48] Evolution of HCV associated porphyria cutanea tarda after HCV sustained virologic response by direct acting antivirals
    Garcia-Fraile, Lucio J.
    Garcia-Buey, Luisa
    Alonso Cerezo, Concepcion
    Sanz Sanz, Jesus
    de los Santos Gil, Ignacio
    GASTROENTEROLOGIA Y HEPATOLOGIA, 2022, 45 (04): : 249 - 255
  • [49] Optimal therapy of HIV/HCV co-infected patients with direct acting antivirals
    Rockstroh, Juergen K.
    LIVER INTERNATIONAL, 2015, 35 : 51 - 55
  • [50] Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma
    Occhipinti, Vincenzo
    Farina, Lucia
    Vigano, Mauro
    Capecchi, Marco
    Labanca, Sara
    Fanetti, Ilaria
    Corradini, Paolo
    Rumi, Mariagrazia
    DIGESTIVE AND LIVER DISEASE, 2019, 51 (05) : 719 - 723